Mon­cef Slaoui

Not long af­ter re­tir­ing from Glax­o­SmithK­line, where he led R&D and then the vac­cines group, Mon­cef Slaoui start­ed sign­ing up for a va­ri­ety of biotech boards. There was a seat at the ta­ble for SutroVax, mR­NA play­er Mod­er­na as well as the pub­lic out­fit In­tel­lia $NT­LA, one of a hand­ful of CRISPR/Ca9 gene edit­ing star­tups dom­i­nat­ing the field.

Then, ear­li­er to­day, he was sud­den­ly gone.

In an SEC fil­ing In­tel­lia not­ed that Slaoui had abrupt­ly de­part­ed on Mon­day “due to a con­flict of in­ter­est.”

That’s it. There was no ex­pla­na­tion of what con­flict had arisen, just that he was off the board. The Boston Busi­ness Jour­nal first re­port­ed the sud­den ex­it.

Slaoui was known for em­brac­ing a slate of po­ten­tial break­through drugs while he was head of R&D, though the com­pa­ny wasn’t able to cap­i­tal­ize on any of them. The block­buster drug can­di­dates ul­ti­mate­ly failed, though GSK has had some big suc­cess­es in HIV and vac­cines. Now GSK is try­ing to re­vamp its pipeline, look­ing to kick­start an oth­er­wise lack­lus­ter de­vel­op­ment group.

Today, we’re opening nominations for our fifth annual Women in Biopharma R&D special report.

Over the last four years, we’ve honored 80 women whose extraordinary accomplishments have changed the game in biopharma R&D. We’re looking for big thinkers, scientists, executives and other enterprising women who are breaking barriers in drug development and inspiring the next generation of leaders.

The FDA on Tuesday released a warning letter sent earlier this month to the Mason, OH-based site of Procter & Gamble Manufactura, raising questions about the list of ingredients on the label and in the electronic filing.

The warning says that for P&G’s over-the-counter Vicks Nyquil Severe Hot Remedy Cold and Flu Plus Congestion, there’s a “mismatched” list of active ingredients between the labeling and the electronic listing file. The listing file for the active ingredients did not match the active ingredients in the electronic file.

The Federal Trade Commission has gotten involved in a patent feud over Supernus’ Parkinson’s drug Apokyn, a case the agency said may have ‘‘significant implications” for patients who rely on the drug.

Sage Chemical won the first generic approval for its Apokyn formulation (also known as apomorphine hydrochloride injection) back in 2022. The non-ergoline dopamine agonist is approved to treat Parkinson’s symptoms during “off episodes,” such as difficulty moving, tremors and intense cramping. However, regulators specified that the approval pertained to the generic drug cartridges only, not the injector pen required for administration.